Leap Investments’s TherapeuticsMD TXMD Stock Holding History

Leap Investments’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-764	Closed	-$99K	–	494
2019 Q2	$99K	Buy	+764	New	+$137K	0.13%	206

Other funds holding TXMD

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Leap Investments's TXMD Position: Q3 2019 in Review

Leap Investments sold out of TherapeuticsMD (TXMD) in Q3 2019, closing a stake of 764 shares — an estimated $99K sold.

Leap Investments first reported a position in TXMD in Q2 2019 and held it in 1 quarter. The position peaked at $99K in Q2 2019. 150 funds tracked by Wall St. Rank hold TXMD as of Q3 2019.

Leap Investments reported no remaining TherapeuticsMD position as of Q3 2019 after selling out during the quarter.
Leap Investments sold 764 TherapeuticsMD shares in Q3 2019, an estimated $99K.
Leap Investments first reported a position in TherapeuticsMD in Q2 2019 and held it in 1 quarter.
Leap Investments's TherapeuticsMD position peaked at $99K in Q2 2019.
150 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2019.

Based on Leap Investments's 13F filing for Q3 2019, filed 13 Nov 2019.